Peregrine Pharmaceuticals Announces First Patient Dosed in Phase II Clinical Trial Evaluating Bavituximab Treatment Combination in Patients with Newly Diagnosed Glioblastoma
September 07, 2017 08:10 ET | Peregrine Pharmaceuticals Inc.
TUSTIN, Calif., Sept. 07, 2017 (GLOBE NEWSWIRE) -- Peregrine Pharmaceuticals, Inc. (NASDAQ:PPHM) (NASDAQ:PPHMP), a biopharmaceutical company committed to improving patient lives by manufacturing...
Peregrine Pharmaceuticals Presents Preliminary Correlative Analysis of PD-L1 Expression from SUNRISE Trial at ASCO 2017
June 05, 2017 08:05 ET | Peregrine Pharmaceuticals Inc.
-- Negative PD-L1 Expression was Associated with a Significantly Longer Median Overall Survival Compared to Positive PD-L1 Expression in Patients Receiving Docetaxel Plus Bavituximab -- -- Presented...
New Study Demonstrates Anti-Tumor Advantages for Combination Treatment Featuring Peregrine Pharmaceuticals’ PS-Targeting Antibodies in a Preclinical Melanoma Model
November 14, 2016 08:05 ET | Peregrine Pharmaceuticals Inc.
-- Promising Results of MSK Study Evaluating Combinations of PS-Targeting Treatment, Anti-PD-1 and Radiation in Mouse B16 Melanoma Model Presented at SITC 2016 -- -- New Data from Second Study...
Preclinical Research Demonstrates Peregrine Pharmaceuticals’ PS-Targeting Antibodies Enhance the Anti-Tumor Activity of PD-L1 Checkpoint Inhibitors in Model of Triple Negative Breast Cancer (TNBC)
October 24, 2016 08:05 ET | Peregrine Pharmaceuticals Inc.
-- Combination of PS-Targeting Antibody and Anti-PD-L1 Therapy, With or Without Chemotherapy, Led to Greater Anti-Tumor Activity Than Single Agent Treatment or Dual Combinations With Chemotherapy -- ...
Peregrine Pharmaceuticals Presents Preclinical Data Demonstrating PS-Targeting Antibodies Significantly Enhance the Anti-Tumor Activity of Multiple Checkpoint Targeting Agents in Model of Triple Negative Breast Cancer (TNBC)
September 27, 2016 08:05 ET | Peregrine Pharmaceuticals Inc.
-- Complete Tumor Regression Seen in 80% of Animals Treated with Triple Combination of PS-Targeting Antibody, Anti-PD-1 Therapy and Anti-Lag3 Therapy vs. 0% of Animals Receiving Double...
Peregrine Pharmaceuticals Reports Financial Results for Third Quarter of Fiscal Year 2016 and Recent Developments
March 09, 2016 08:00 ET | Peregrine Pharmaceuticals Inc.
--Company Focused on Advancing Its Bavituximab Immuno-Oncology Program Through Its Pharmaceutical, Academic and Clinical Collaborations-- --Full Fiscal Year 2016 Revenue From Biomanufacturing...
Peregrine Pharmaceuticals Declares Quarterly Dividend on Its Series E Convertible Preferred Stock
March 07, 2016 16:05 ET | Peregrine Pharmaceuticals Inc.
TUSTIN, Calif., March 07, 2016 (GLOBE NEWSWIRE) -- Peregrine Pharmaceuticals, Inc. (Nasdaq:PPHM) (Nasdaq:PPHMP) today announced that its Board of Directors has declared a quarterly cash dividend...
Peregrine Pharmaceuticals to Present at Two Upcoming Cancer Immunotherapy Conferences
January 20, 2016 08:05 ET | Peregrine Pharmaceuticals Inc.
TUSTIN, Calif., Jan. 20, 2016 (GLOBE NEWSWIRE) -- Peregrine Pharmaceuticals, Inc. (NASDAQ:PPHM) (NASDAQ:PPHMP), a biopharmaceutical company focused on developing therapeutics to stimulate the...
Peregrine Pharmaceuticals Reports Financial Results for Second Quarter of Fiscal Year 2016 and Recent Developments
December 10, 2015 16:05 ET | Peregrine Pharmaceuticals Inc.
  --Peregrine and AstraZeneca Expand Immuno-Oncology Collaboration and Plan Phase II NSCLC Trial-- --Phase III SUNRISE Clinical Trial Expected to Complete Enrollment in Coming Weeks While New...
Peregrine Pharmaceuticals Reports Financial Results for First Quarter of Fiscal Year 2016 and Recent Developments
September 09, 2015 16:05 ET | Peregrine Pharmaceuticals Inc.
--Peregrine and AstraZeneca to Collaborate on Immuno-Oncology Combination Clinical Trial-- --Phase III SUNRISE Clinical Trial on Track to Complete Patient Enrollment by Calendar Year-End 2015-- ...